Program
palazestrant
Also written as “Palazestrant” and “OP-1250”.
Its studies are mostly in Breast Neoplasms, led by Olema Pharmaceuticals.
Furthest: phase 3, since Aug 17, 20234 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Olema Pharmaceuticals | 43 open or running | phase 3since Aug 17, 2023 | Jul 21, 2020 | Dec 2028phase 3 · NCT07085767 |
Also a collaborator on its studies: Novartis and Pfizer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2020First study: phase 2 study in Hormone Receptor Positive Breast CarcinomaFirst studyNCT04505826 · 153 enrolled · United States, Australia
- Feb 11, 2022Phase 1 study in Breast NeoplasmsNCT05266105 · 60 enrolled · Australia
- Aug 17, 2023Phase 3 study in Breast NeoplasmsNCT06016738 · 510 enrolled · United States, Argentina, Australia and more
- Jul 8, 2025Phase 3 study in Breast NeoplasmsNCT07085767 · 1,000 planned · United States, Australia, Austria and more
Ahead
- Dec 2028Primary completion: phase 3 study in Breast NeoplasmsNCT07085767
TargetBeta
ESR1 →read by rule
“An orally available, small molecule antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1) and a selective ER degrader (SERD), ”NCIt, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07085767Breast Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Dec 2028 | 1,000 |
| NCT06016738Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 31, 2026 | 510 |
| NCT05266105Breast Neoplasms · Australia | 1 | Active, not recruiting | Mar 2026 | 60 |
| NCT04505826Hormone Receptor Positive Breast Carcinoma · United States, Australia | 2 | Completed | Jul 30, 2024 | 153 |
How it is read
Names in the registry
- “Palazestrant”, 3 entries
- “OP-1250”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.